FIG 2.

Individual afabicin desphosphono concentrations in plasma (A), cortical bone (B), cancellous bone (C), synovial fluid (D), bone marrow (E), and soft tissue (F) after the third oral dose of afabicin (240 mg, q12h) in patients undergoing hip replacement surgery. Data are from 14 patients, with the following exceptions: for 1 patient, the plasma sample was missing at the time of resection and the plasma concentration was extrapolated by linear regression between the two adjacent concentration data from the full PK profile in plasma. Synovial fluid was obtained for 8 patients only. For one patient no results except for plasma were reportable at the time of resection, and for another, only plasma, soft tissue, and bone marrow were collected at the time of resection.